MEDTOX Scientific Increases Sales but Misses Estimates on Earnings
MEDTOX Scientific (NAS: MTOX) reported earnings on July 12. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), MEDTOX Scientific met expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share dropped.
Margins shrank across the board.
MEDTOX Scientific logged revenue of $30.0 million. The two analysts polled by S&P Capital IQ expected revenue of $30.3 million on the same basis. GAAP reported sales were 7.4% higher than the prior-year quarter's $27.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.17. The two earnings estimates compiled by S&P Capital IQ predicted $0.21 per share. GAAP EPS of $0.14 for Q2 were 13% lower than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 42.1%, 120 basis points worse than the prior-year quarter. Operating margin was 6.3%, 150 basis points worse than the prior-year quarter. Net margin was 4.1%, 90 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $30.6 million. On the bottom line, the average EPS estimate is $0.23.
Next year's average estimate for revenue is $119.3 million. The average EPS estimate is $0.78.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 154 members out of 163 rating the stock outperform, and nine members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give MEDTOX Scientific a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDTOX Scientific is underperform, with an average price target of $27.00.
Over the decades, small-cap stocks, like MEDTOX Scientific have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add MEDTOX Scientific to My Watchlist.
The article MEDTOX Scientific Increases Sales but Misses Estimates on Earnings originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.